Daflon 500 mg - cacvs
Daflon 500 mg - cacvs
Daflon 500 mg - cacvs
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Author,<br />
year<br />
Shadid N,<br />
2012<br />
Rass K,<br />
2012<br />
Nordon<br />
IM, 2011<br />
Liu X,<br />
2011<br />
Rasmussen<br />
LH, 2011<br />
Disselhoff<br />
BC, 2011<br />
Chan<br />
CY,2011<br />
Jia X,<br />
2011<br />
Blo<strong>mg</strong>ren<br />
L, 2011<br />
Schul<br />
MW, 2011<br />
Carradice<br />
D, 2011<br />
Carradice<br />
D, 2011<br />
Christenson<br />
JT, 2010<br />
Dimension Procedure Follow-up<br />
430 patients UGFS vs. HL/S<br />
Baseline, month 3, year 1<br />
and 2<br />
QoL<br />
questionnaire<br />
EQ-5D<br />
400 patients EVLA vs. HL/S Year 2 CIVIQ<br />
159 patients EVLA vs. RFA<br />
60 patients<br />
<strong>500</strong> patients<br />
(580 legs)<br />
120 patients<br />
UGFS + SFJ ligation vs.<br />
conventional stripping<br />
EVLA vs. RFA vs. UGFS<br />
vs. Stripping<br />
EVLA<br />
vs. Cryostripping<br />
82 patients EVLA vs. CHIVA<br />
60 patients<br />
227 patients<br />
58 patients<br />
280 patients<br />
280 patients<br />
Comparative studies (1/2)<br />
Foam sclerotherapy +<br />
SFJ ligation vs.<br />
conventional stripping<br />
Preoperative duplex<br />
examination + Surgery<br />
vs. Only surgery<br />
Sclerotherapy vs.<br />
Stocking (crossover to<br />
sclerotherapy)<br />
EVLA<br />
vs. Surgery*<br />
EVLA<br />
vs. Surgery*<br />
Pre-operative and<br />
month 3<br />
AVVQ+ EQ-5D<br />
Conclusion<br />
At year 2 follow-up, UGFS was not inferior to<br />
surgery.<br />
Both EVLT and HLS are comparably safe and<br />
effective procedures to treat GSV incompetence.<br />
Changes in the AVVQ and<br />
EQ-5D at 3 months were similar in both groups.<br />
Month 3 and 6 AVVQ -<br />
Pre-operative, day 3,<br />
month 1 and year 1<br />
EQ-5D<br />
+SF36<br />
Year 5 AVVSS<br />
Week 1 and month 1, 3, 6<br />
and 12<br />
AVVQ<br />
Months 3 and 6 -<br />
Year 7 (late follow-up<br />
study)<br />
T0, after compression trial,<br />
after sclerotherapy and month<br />
3 and 12 after sclerotherapy,<br />
SF36<br />
AVVQ<br />
Week 1, 6, 12 and 52 AVVQ<br />
- AVVQ + SF36<br />
Disease-specific quality-of-life and SF-36 scores had<br />
improved in all groups by 1 year follow-up.<br />
AVVSS improved significantly after treatment in both<br />
groups, with no significant difference between them.<br />
Both groups benefited significantly from surgery in<br />
disease-specific perceptions.<br />
Foam sclerotherapy + SFJ ligation involves a less<br />
postoperative discomfort<br />
QoL was similar in both groups, but routine<br />
preoperative duplex imaging improved the results of<br />
surgery for primary varicose veins for at least 7 year<br />
Sclerotherapy offers a statistically superior broad<br />
spectrum relief of symptoms.<br />
Clinical recurrence was associated with worse AVVQ<br />
scores<br />
EVLA had a less negative impact on early<br />
postintervention QoL<br />
204 legs EVLA vs. HL/S Day 12, year 1, year 2 AVVSS + SF36 Similar QoL improvement after HL/S and EVLA
Change language